Literature DB >> 33720773

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options.

Joachim Jankowski1,2, Jürgen Floege3, Danilo Fliser4, Michael Böhm5, Nikolaus Marx6.   

Abstract

Patients with chronic kidney disease (CKD) exhibit an elevated cardiovascular risk manifesting as coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. Although the incidence and prevalence of cardiovascular events is already significantly higher in patients with early CKD stages (CKD stages 1-3) compared with the general population, patients with advanced CKD stages (CKD stages 4-5) exhibit a markedly elevated risk. Cardiovascular rather than end-stage kidney disease (CKD stage 5) is the leading cause of death in this high-risk population. CKD causes a systemic, chronic proinflammatory state contributing to vascular and myocardial remodeling processes resulting in atherosclerotic lesions, vascular calcification, and vascular senescence as well as myocardial fibrosis and calcification of cardiac valves. In this respect, CKD mimics an accelerated aging of the cardiovascular system. This overview article summarizes the current understanding and clinical consequences of cardiovascular disease in CKD.

Entities:  

Keywords:  arrhythmias; cardiovascular disease; chronic kidney disease; clinical aspects; death; heart failure; sudden cardiac

Mesh:

Year:  2021        PMID: 33720773      PMCID: PMC7969169          DOI: 10.1161/CIRCULATIONAHA.120.050686

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  131 in total

Review 1.  Clinical epidemiology of cardiovascular disease in chronic renal disease.

Authors:  R N Foley; P S Parfrey; M J Sarnak
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

Review 2.  Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension.

Authors:  Emine Meltem Onal; Alan Alper Sag; Oguzhan Sal; Aslihan Yerlikaya; Baris Afsar; Mehmet Kanbay
Journal:  Clin Exp Hypertens       Date:  2017       Impact factor: 1.749

Review 3.  Blood pressure targets and kidney and cardiovascular disease: same data but discordant guidelines.

Authors:  Bethany Roehm; Daniel E Weiner
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-05       Impact factor: 2.894

4.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

Review 5.  Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators.

Authors:  Alessia Buglioni; John C Burnett
Journal:  Clin Chim Acta       Date:  2014-10-23       Impact factor: 3.786

Review 6.  Electrolyte and Acid-Base Disorders in Chronic Kidney Disease and End-Stage Kidney Failure.

Authors:  Tsering Dhondup; Qi Qian
Journal:  Blood Purif       Date:  2017-01-24       Impact factor: 2.614

7.  Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification.

Authors:  Silvia Salem; Heike Bruck; Ferdinand H Bahlmann; Mirjam Peter; Jutta Passlick-Deetjen; Axel Kretschmer; Sonja Steppan; Michaela Volsek; Andreas Kribben; Marc Nierhaus; Vera Jankowski; Walter Zidek; Joachim Jankowski
Journal:  Am J Nephrol       Date:  2011-12-15       Impact factor: 3.754

8.  Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Authors:  George L Bakris; Rajiv Agarwal; Juliana C Chan; Mark E Cooper; Ron T Gansevoort; Hermann Haller; Giuseppe Remuzzi; Peter Rossing; Roland E Schmieder; Christina Nowack; Peter Kolkhof; Amer Joseph; Alexander Pieper; Nina Kimmeskamp-Kirschbaum; Luis M Ruilope
Journal:  JAMA       Date:  2015-09-01       Impact factor: 56.272

9.  The Framingham predictive instrument in chronic kidney disease.

Authors:  Daniel E Weiner; Hocine Tighiouart; Essam F Elsayed; John L Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak
Journal:  J Am Coll Cardiol       Date:  2007-07-02       Impact factor: 24.094

10.  Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.

Authors:  Yoshihiro Matsumoto; Yasuo Mori; Shinji Kageyama; Kazuo Arihara; Toshikazu Sugiyama; Hiromichi Ohmura; Toru Yakushigawa; Hatsumi Sugiyama; Yasushi Shimada; Youichi Nojima; Nobuo Shio
Journal:  J Am Coll Cardiol       Date:  2013-10-30       Impact factor: 24.094

View more
  92 in total

Review 1.  Cardiac Complications: The Understudied Aspect of Cancer Cachexia.

Authors:  Vivek Bora; Bhoomika Patel
Journal:  Cardiovasc Toxicol       Date:  2022-02-16       Impact factor: 3.231

Review 2.  Kidney and heart failure outcomes associated with SGLT2 inhibitor use.

Authors:  Annemarie B van der Aart-van der Beek; Rudolf A de Boer; Hiddo J L Heerspink
Journal:  Nat Rev Nephrol       Date:  2022-02-10       Impact factor: 28.314

Review 3.  Update on Management of Cardiovascular Diseases in Women.

Authors:  Fabiana Lucà; Maurizio Giuseppe Abrignani; Iris Parrini; Stefania Angela Di Fusco; Simona Giubilato; Carmelo Massimiliano Rao; Laura Piccioni; Laura Cipolletta; Bruno Passaretti; Francesco Giallauria; Angelo Leone; Giuseppina Maura Francese; Carmine Riccio; Sandro Gelsomino; Furio Colivicchi; Michele Massimo Gulizia
Journal:  J Clin Med       Date:  2022-02-22       Impact factor: 4.241

4.  New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice.

Authors:  Marc Evans; Angharad R Morgan; Martin B Whyte; Wasim Hanif; Stephen C Bain; Philip A Kalra; Sarah Davies; Umesh Dashora; Zaheer Yousef; Dipesh C Patel; W David Strain
Journal:  Drugs       Date:  2021-12-21       Impact factor: 9.546

5.  Changes in the size and electrophoretic mobility of HDL subpopulation particles in chronic kidney disease.

Authors:  Anna Gliwińska; Agnieszka Ćwiklińska; Monika Czaplińska; Ewa Wieczorek-Breitzke; Barbara Kortas-Stempak; Agnieszka Kuchta; Alicja Dębska-Ślizień; Ewa Król; Maciej Jankowski
Journal:  J Nephrol       Date:  2022-08-09       Impact factor: 4.393

6.  Cardiac micro-RNA and transcriptomic profile of a novel swine model of chronic kidney disease and left ventricular diastolic dysfunction.

Authors:  Alejandro R Chade; Alfonso Eirin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-08-26       Impact factor: 5.125

7.  Intrarenal modulation of NF-κB activity attenuates cardiac injury in a swine model of CKD: a renal-cardio axis.

Authors:  Alejandro R Chade; Jason E Engel; Michael E Hall; Alfonso Eirin; Gene L Bidwell
Journal:  Am J Physiol Renal Physiol       Date:  2021-08-16

Review 8.  Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.

Authors:  Luis D'Marco; María Jesús Puchades; Lorena Gandía; Claudia Forquet; Elena Giménez-Civera; Nayara Panizo; Javier Reque; Isabel Juan-García; Valmore Bermúdez; José Luis Gorriz
Journal:  touchREV Endocrinol       Date:  2021-11-10

Review 9.  Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?

Authors:  Susana Coimbra; Flávio Reis; Maria João Valente; Susana Rocha; Cristina Catarino; Petronila Rocha-Pereira; Maria Sameiro-Faria; Elsa Bronze-da-Rocha; Luís Belo; Alice Santos-Silva
Journal:  Biomedicines       Date:  2021-05-16

10.  Association between Reduced Serum Zinc and Diastolic Dysfunction in Maintenance Hemodialysis Patients.

Authors:  Jiun-Chi Huang; Ya-Chin Huang; Pei-Yu Wu; Wen-Hsien Lee; Yi-Chun Tsai; Yi-Ping Chen; Szu-Chia Chen; Ho-Ming Su; Yi-Wen Chiu; Jer-Ming Chang
Journal:  Nutrients       Date:  2021-06-17       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.